FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment - Muscular Dystrophy Association

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPa0ZNS01rRUd5UzBEa0…; target="_blank">FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment</a>&nbsp;&nbsp;<font color="#6f6f6f">Muscular Dystrophy Association</font>